2-[[((pyridin-4-yl)methyl)hydroxyphosphinyl]methyl]pentanedioic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-[[((pyridin-4-yl)methyl)hydroxyphosphinyl]methyl]pentanedioic acid
• 英文别名: 2-[[((4-pyridyl)methyl)hydroxyphosphinyl]methyl]pentanedioic acid；2-[[Hydroxy(pyridin-4-ylmethyl)phosphoryl]methyl]pentanedioic acid
• 化学式: C₁₂H₁₆NO₆P
• 分子量: 301.236
• InChiKey: WIJGRKWAABBWJZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.3
• 重原子数：
  20
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  125
• 氢给体数：
  3
• 氢受体数：
  7

文献信息

• PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING
  申请人：Purdue Research Foundation

  公开号：US20160067341A1

  公开（公告）日：2016-03-10

  Described herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical composition containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them.

  本文描述了用于传递治疗、诊断和成像剂的前列腺特异性膜抗原（PSMA）结合共轭物。本文还描述了含有它们的药物组合物以及使用这些共轭物和组合物的方法。还描述了用于制造这些共轭物和含有它们的组合物的过程。
• [EN] CANCER IMAGING AGENT<br/>[FR] AGENT D'IMAGERIE DU CANCER
  申请人：ENDOCYTE INC

  公开号：WO2016112293A1

  公开（公告）日：2016-07-14

  The present disclosure relates to imaging agent formulations, methods for preparing imaging agent formulations and methods for using the same. The present disclosure also relates to kits for imaging agent formulations.

  本公开涉及成像剂配方、制备成像剂配方的方法以及使用它们的方法。本公开还涉及成像剂配方的套件。
• [EN] PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING<br/>[FR] CONJUGUÉS LIGAND-LIEUR DE LIAISON AU PSMA ET PROCÉDÉS POUR UTILISER CEUX-CI
  申请人：PURDUE RESEARCH FOUNDATION

  公开号：WO2009026177A1

  公开（公告）日：2009-02-26

  Described herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical composition containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them.

  本文描述了前列腺特异性膜抗原（PSMA）结合的联合物，可以用于输送治疗、诊断和成像剂。还描述了包含它们的制药组合物以及使用这些联合物和组合物的方法。还描述了制造这些联合物和包含它们的组合物的过程。
• Pharmaceutical compositions and methods of inhibiting angiogenesis using NAALADase inhibitors
  申请人：——

  公开号：US20030064912A1

  公开（公告）日：2003-04-03

  The present disclosure relates to a method of inhibiting angiogenesis comprising administering a N-Acetylated &agr;-Linked Acidic Dipeptidase (NAALADase) inhibitor to a patient in need thereof, and a pharmaceutical composition comprising an anti-angiogenic effective amount of a NAALADase inhibitor and a pharmaceutically acceptable carrier.

  本公开涉及一种抑制血管生成的方法，包括向需要该方法的患者给予N-乙酰化的α-连接酸性二肽酶（NAALADase）抑制剂，以及包含抗血管生成有效量的NAALADase抑制剂和药用载体的制药组合物。
• Methods of cancer treatment using naaladase inhibitors
  申请人：——

  公开号：US20020151503A1

  公开（公告）日：2002-10-17

  The present disclosure relates to dipeptidase inhibitors, and more particularly, to novel methods of using phosphonate derivatives, hydroxyphosphinyl derivatives, and phosphoramidate derivatives to inhibit N-Acetylated &agr;-Linked Acidic Dipeptidase (NAALADase) enzyme activity, and to treat prostate diseases, especially using the compounds of the present invention for the inhibition of the growth of prostate cancer cells.

  本公开涉及二肽酶抑制剂，更具体地涉及使用磷酸酯衍生物、羟基膦酰衍生物和磷酰胺衍生物的新方法来抑制N-乙酰化的α-连接酸性二肽酶（NAALADase）酶活性，并治疗前列腺疾病，特别是使用本发明的化合物来抑制前列腺癌细胞的生长。